Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial
about
Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysisWhat can we offer to 3 million MDRTB household contacts in 2016?A 20-year retrospective cohort study of TB infection among the Hill-tribe HIV/AIDS populations, ThailandUpdates on the risk factors for latent tuberculosis reactivation and their managementsTB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysisControlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infectionA Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort StudyEffect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review.HIV care in Yangon, Myanmar; successes, challenges and implications for policy.Timing of antiretroviral therapy and TB treatment outcomes in patients with TB-HIV in MyanmarThe rise and fall of tuberculosis in Malawi: associations with HIV infection and antiretroviral therapy.Recurrent tuberculosis and associated factors: A five - year countrywide study in UzbekistanUpdate in Mycobacterium tuberculosis lung disease 2014.Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India.Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit impaired lung CD4(+) T-cell responses to mycobacteria.Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot.TB TestDebunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons.Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study.What's next for tuberculosis control in sub-Saharan Africa?Enhancing the impact of antiretroviral scale-up on the HIV-associated tuberculosis epidemic in MalawiPredictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil.Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method design.Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study.Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected personsEmpirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trialCost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in IndiaDeclining tuberculosis case notification rates with the scale-up of antiretroviral therapy in ZimbabweHIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up.Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis.Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana.Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative tuberculosis.Mycobacterium tuberculosis: 2014 Clinical trials in reviewIsoniazid for preventing tuberculosis in HIV-infected children.Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV.Screening and treatment of latent tuberculosis infection among HIV-infected patients in resource-rich settings.Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
P2860
Q26798435-67E84DEB-30E2-4E39-A2EF-A55F305EAB7AQ28066845-995A77F0-1BB3-4DF5-8CB0-ADBCCA349BCDQ28070006-3ED8BCDA-CBE8-4521-A6B2-F126E73E366EQ28073158-58875375-C40F-4286-8095-80D2912412FDQ28073480-03315E9A-E8B7-41B9-8204-B298C0B4691DQ28087385-6B220015-B980-4EE7-B5CD-6CE159687713Q28547313-8DC6C7DD-441A-4D88-9667-34BB3DD0854DQ30240445-54DAF506-2230-4B62-8289-FC34289FC10FQ30378383-E0C0E4C7-6DE5-4ED2-AA68-96ED87B6571CQ30383131-09E4C933-6FDF-4171-BFC6-79FC8E9F6BBDQ30385976-174FC2FD-7A27-48D7-816B-FB887A8C71D0Q33637577-07FCDBF6-D415-4839-A28A-5AFC0395B6C2Q33735642-2FF5A41C-2E32-4A2C-B1B0-057D26CEAE21Q34675209-6F408EA3-F8E3-4DDA-B5C2-E01EC2EAEFF9Q34986921-FB4C798D-15DD-4062-AD2B-4B6B0162B2D3Q35197248-0E96C09A-4DC8-4C53-84AE-FE8C08C2CB64Q35566421-B7B3E56D-71B8-48CC-B65C-5B63297117D1Q35567798-C1971B94-A4DB-45D9-AC84-96079761D422Q35577840-87097683-FF34-4B5A-87A3-A0B227D407E3Q35744636-B7FFCC36-11F7-4164-966A-A87847A348EDQ35944833-8ECB39B2-1BA1-4AFD-AA41-037E757294A2Q35944889-71544F74-5AF6-406B-870F-61B7093014A1Q35965602-46549161-EDD1-4677-9B3D-FE6DDA1CFE59Q36120455-E0A2E9C3-2C06-40B4-96CD-75C39F72E881Q36287555-E967133A-36AD-45F1-A9AF-BC274053B17CQ36720436-80776E51-8680-41C7-9704-3A0E04737A51Q36986755-BF069535-0070-48E2-AA03-C5DCC9641A9BQ37061089-F6E1B99B-5128-432D-8506-BE924208A74CQ37192288-3CB83915-F72A-4ABE-8FED-C098699FFB23Q37279224-CFE505D2-F469-4A56-81AD-A3921A9F8313Q37328357-F3FD200B-DCB5-4CD2-9891-40D4601850C3Q37461120-74D8E558-B916-4B83-A7BA-D05725DA0982Q37461125-CBD8F304-742C-4DA4-9ADE-7D9FE5D8F261Q37524217-6C130EAA-B1E1-4FA0-9EE9-DA3D516892D7Q38387116-4588616C-AD36-4FDD-B58B-8182C0AA30E8Q38604018-3A06907C-73B5-4E13-A701-043B36C8DCDBQ38686803-F38FEB39-117F-4901-B117-DDF6C8FC2847Q38783382-A2138DB0-8696-4DC0-BAF7-3C9EFD3F700AQ38841837-E8E94A20-4561-4C4C-AF9C-E25E56B927EFQ38849598-E3791B3C-6D73-48F6-91A6-8FAB4D33A6B3
P2860
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@ast
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@en
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@nl
type
label
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@ast
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@en
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@nl
prefLabel
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@ast
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@en
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@nl
P2093
P2860
P50
P921
P1433
P1476
Isoniazid plus antiretroviral ...... lind, placebo-controlled trial
@en
P2093
Eric Goemaere
Judith R Glynn
Katherine Fielding
Molebogeng X Rangaka
Rene Goliath
Shaheed Mathee
P2860
P304
P356
10.1016/S0140-6736(14)60162-8
P407
P577
2014-05-13T00:00:00Z